Literature DB >> 36129564

Reversal of IgG4-related aortitis after treatment evidenced by [18F]FDG PET/CT.

Thamyze Mirellly Piva1, Carlos Roberto de Faria Junior2, Mery Kato1, Fabíola Reis de Oliveira2, Paulo Louzada2, Lauro Wichert-Ana3,4.   

Abstract

Entities:  

Year:  2022        PMID： 36129564     DOI： 10.1007/s10067-022-06374-x

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   3.650


× No keyword cloud information.
  5 in total

Review 1.  Vasculitis beyond aortitis in IgG4-related disease (IgG4-RD): case report and review of the literature.

Authors:  George E Fragoulis; Gerasimos Evangelatos; Maria G Tektonidou
Journal:  Clin Rheumatol       Date:  2020-07-24       Impact factor: 2.980

2.  The value of (18)F-FDG PET/CT in Diagnosis and Evaluation of Response to Treatment in Retroperitoneal Fibrosis.

Authors:  Mehmet Tarik Tatoglu; Hatice Uslu; Ebru Ibisoglu
Journal:  Nuklearmedizin       Date:  2021-04-09       Impact factor: 1.379

3.  Hidden IgG4-Related Coronary Disease.

Authors:  Namita Ramdin; Matthew Orde; Siobhán B O'Neill; Chi Lai; Jennifer D Pors; Michael Multan; Luke Y C Chen; Mollie N Carruthers
Journal:  Am J Clin Pathol       Date:  2021-08-04       Impact factor: 2.493

Review 4.  Overview of IgG4-related aortitis and periaortitis. A decade since their first description.

Authors:  Elena Nikiphorou; James Galloway; George E Fragoulis
Journal:  Autoimmun Rev       Date:  2020-10-22       Impact factor: 9.754

Review 5.  The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease.

Authors:  Zachary S Wallace; Ray P Naden; Suresh Chari; Hyon K Choi; Emanuel Della-Torre; Jean-Francois Dicaire; Phillip A Hart; Dai Inoue; Mitsuhiro Kawano; Arezou Khosroshahi; Marco Lanzillotta; Kazuichi Okazaki; Cory A Perugino; Amita Sharma; Takako Saeki; Nicolas Schleinitz; Naoki Takahashi; Hisanori Umehara; Yoh Zen; John H Stone
Journal:  Ann Rheum Dis       Date:  2019-12-03       Impact factor: 19.103
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.